Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study

[1]  T. Dalziel.  Chronic Interstitial Enteritis , 2018 .

[2]  R. Rock.  Inflammatory Bowel Disease in Adults , 2017 .

[3]  Hailiang Huang,et al.  High density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis , 2014, Nature Genetics.

[4]  P. Visscher,et al.  Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. , 2014, Human molecular genetics.

[5]  Subrata Ghosh,et al.  Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. , 2013, Gastroenterology.

[6]  J. Barrett,et al.  Using Genetic Prediction from Known Complex Disease Loci to Guide the Design of Next-Generation Sequencing Experiments , 2013, PloS one.

[7]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[8]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[9]  M. Neovius,et al.  Patients with ulcerative colitis miss more days of work than the general population, even following colectomy. , 2013, Gastroenterology.

[10]  J. González,et al.  Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project , 2012, Gut.

[11]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[12]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[13]  Timothy L. Tickle,et al.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.

[14]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[15]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[16]  R. Xavier,et al.  Genetics and pathogenesis of inflammatory bowel disease , 2011, Nature.

[17]  C. Lees,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2011, Gut.

[18]  G. Kirov,et al.  Polygenic dissection of the bipolar phenotype , 2011, British Journal of Psychiatry.

[19]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[20]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[21]  Andre Franke,et al.  Genetic risk profiling and prediction of disease course in Crohn's disease patients. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  J. Everhart,et al.  Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. , 2009, Gastroenterology.

[23]  M. Vatn,et al.  Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) , 2009, Scandinavian journal of gastroenterology.

[24]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[25]  M. Vatn,et al.  Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[27]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[28]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[29]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[30]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[31]  G. V. Rosendaal.  in In fl ammatory Bowel Disease , 2005 .

[32]  A. Zinsmeister,et al.  PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis , 2004, Gut.

[33]  J. Ioannidis,et al.  Differential Effects of NOD2 Variants on Crohn's Disease Risk and Phenotype in Diverse Populations: A Metaanalysis , 2004, The American Journal of Gastroenterology.

[34]  M. Silverberg,et al.  CARD15 and HLA DRB1 Alleles Influence Susceptibility and Disease Localization in Crohn's Disease , 2004, American Journal of Gastroenterology.

[35]  Judy H. Cho,et al.  Defining Complex Contributions of NOD2/CARD15 Gene Mutations, Age at Onset, and Tobacco Use On Crohn's Disease Phenotypes , 2003, Inflammatory bowel diseases.

[36]  E. Lindberg,et al.  Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. , 2003, Gastroenterology.

[37]  Lucia Mirea,et al.  A Population- and Family-Based Study of Canadian Families Reveals Association of HLA DRB1*0103 With Colonic Involvement in Inflammatory Bowel Disease , 2003, Inflammatory bowel diseases.

[38]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[39]  Alastair Forbes,et al.  The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. , 2002, Gastroenterology.

[40]  T. Ahmad,et al.  The molecular classification of the clinical manifestations of Crohn's disease. , 2002, Gastroenterology.

[41]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[42]  E. G. de la Concha,et al.  Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. , 2000, Gastroenterology.

[43]  K. Boberg,et al.  HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. , 1999, Tissue antigens.

[44]  M. Vatn,et al.  Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. , 1997, Gut.

[45]  D. Podolsky,et al.  Inflammatory bowel disease (1) , 1991, The New England journal of medicine.

[46]  B. Portmann,et al.  Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis , 1991, Hepatology.

[47]  T. Dalziel,et al.  Thomas Kennedy Dalziel 1861–1924 , 1989 .

[48]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[49]  T. Dalziel.  Thomas Kennedy Dalziel 1861-1924. Chronic interstitial enteritis. , 1989, Diseases of the colon and rectum.

[50]  V. Ponti,et al.  Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. , 1987, Gastroenterology.

[51]  M. Larkin,et al.  Ulcerative Colitis in Children , 1961, Southern medical journal (Birmingham, Ala. Print).

[52]  G. Oppenheimer,et al.  Regional ileitis; a pathologic and clinical entity. , 1952, The American journal of medicine.